Johnson & Johnson announced on Friday that its COVID-19 vaccine was 66% effective overall in the global trial, Reuters reported. The company further noted that the vaccine was 72% effective in the US portion of the trial.
Market reaction
This headline seems to be weighing heavily on market confidence. At time of writing, S&P 500 futures were down 1.2% on the day. Meanwhile, Germany’s DAX 30 lost 1.35% and the UK’s FTSE 100 lost 1.9%.
Additional conclusions
“The vaccine is 57% effective in the South African portion of the trial.”
“The vaccine has an overall efficacy of 85% in preventing serious diseases.”
“The single-dose covid vaccine was generally well tolerated.”
“Seeking to apply for US emergency use authorization in early February.”
“It will have the vaccine ready to ship immediately after authorization.”
“Hoping to meet vaccine supply commitments by 2021.”
.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
